CLSD · As filed with the SEC
Clearside Biomedical balance sheet, by fiscal year
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 | FY2020 Dec 31, 2020 | FY2019 Dec 31, 2019 | FY2018 Dec 31, 2018 | FY2017 Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | 20,020,000 | 28,920,000 | 48,258,000 | 30,436,000 | 17,287,000 | 22,595,000 | 8,043,000 | 9,224,000 |
| Short-term investments | — | — | — | — | — | — | 32,835,000 | 28,416,000 |
| Accounts receivable | 507,000 | 170,000 | 0 | 10,000,000 | — | — | — | — |
| Prepaid expenses | 734,000 | 722,000 | 704,000 | 921,000 | 722,000 | 1,139,000 | 2,049,000 | 1,445,000 |
| Other current assets | 13,000 | 311,000 | 439,000 | 779,000 | 109,000 | 1,485,000 | 17,000 | 116,000 |
| Total current assets | 21,274,000 | 30,123,000 | 49,401,000 | 42,136,000 | 18,118,000 | 25,219,000 | 42,944,000 | 39,201,000 |
| Property and equipment, net | 3,225,000 | 2,996,000 | 755,000 | 238,000 | 416,000 | 541,000 | 790,000 | 885,000 |
| Operating lease right-of-use asset | 597,000 | 869,000 | 1,117,000 | 369,000 | 528,000 | 656,000 | — | — |
| Restricted cash and other assets | — | — | 30,000 | 160,000 | 260,000 | 360,000 | 360,000 | 360,000 |
| Other assets | 30,000 | 30,000 | — | — | — | — | 26,000 | 47,000 |
| Total assets | 25,126,000 | 34,018,000 | 51,303,000 | 42,903,000 | 19,322,000 | 26,776,000 | 44,120,000 | 40,493,000 |
| Liabilities and stockholders' deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable (includes $491 and $331 to a related party as of December 31, 2024 and 2023, respectively) | 1,452,000 | 2,205,000 | 1,050,000 | 941,000 | 1,997,000 | 1,280,000 | 6,869,000 | 5,384,000 |
| Accrued liabilities (includes $304 and $215 to a related party as of December 31, 2024 and 2023, respectively) | 2,967,000 | 4,169,000 | 4,179,000 | 3,312,000 | 1,582,000 | 2,930,000 | 2,923,000 | 4,716,000 |
| Current portion of long-term debt | — | — | — | — | 991,000 | 1,333,000 | 556,000 | 3,200,000 |
| Current portion of operating lease liabilities | 375,000 | 364,000 | 349,000 | 387,000 | 373,000 | 360,000 | — | — |
| Current portion of deferred rent | — | — | — | — | — | — | 128,000 | 199,000 |
| Other current liabilities | — | — | — | — | — | — | — | 20,000 |
| Deferred revenue | 0 | 75,000 | 205,000 | — | 5,000,000 | 5,000,000 | — | — |
| Total current liabilities | 4,794,000 | 6,813,000 | 5,783,000 | 4,640,000 | 9,943,000 | 10,903,000 | 10,476,000 | 13,519,000 |
| Long-term debt | — | — | — | — | — | 3,819,000 | 9,419,000 | 4,809,000 |
| Liability related to the sales of future royalties, net | 51,767,000 | 41,988,000 | 33,977,000 | — | — | — | — | — |
| Warrant liabilities | 6,692,000 | — | — | — | — | — | — | — |
| Operating lease liabilities | 328,000 | 649,000 | 936,000 | 288,000 | 616,000 | 897,000 | — | — |
| Deferred rent | — | — | — | — | — | — | 605,000 | 610,000 |
| Deferred revenue | — | — | — | — | — | — | — | 140,000 |
| Other non-current liabilities | 400,000 | 480,000 | — | — | — | — | — | — |
| Total liabilities | 63,981,000 | 49,930,000 | 40,696,000 | 4,928,000 | 10,559,000 | 15,619,000 | 20,500,000 | 19,078,000 |
| Stockholders' deficit: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at December 31, 2024 and 2023 | 0 | 0 | 0 | — | — | — | — | — |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 76,578,383 and 62,850,841 shares issued and outstanding at December 31, 2024 and 2023, respectively | 77,000 | 63,000 | 61,000 | 60,000 | 52,000 | 44,000 | 32,000 | 25,000 |
| Additional paid-in capital | 316,343,000 | 304,948,000 | 298,984,000 | 293,406,000 | 264,578,000 | 248,770,000 | 230,475,000 | 145,618,000 |
| Accumulated deficit | (355,275,000) | (320,923,000) | (288,438,000) | (255,491,000) | (255,867,000) | (237,657,000) | (206,887,000) | (124,220,000) |
| Accumulated other comprehensive loss | — | — | — | — | — | — | — | (8,000) |
| Total stockholders' deficit | (38,855,000) | (15,912,000) | 10,607,000 | 37,975,000 | 8,763,000 | 11,157,000 | 23,620,000 | 21,415,000 |
| Total liabilities and stockholders' deficit | 25,126,000 | 34,018,000 | 51,303,000 | 42,903,000 | 19,322,000 | 26,776,000 | 44,120,000 | 40,493,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.